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Abstract: The existence of a supramolecular organization of the G protein-coupled receptor (GPCR) is now being widely 
accepted by the scientific community. Indeed, GPCR oligomers may enhance the diversity and performance by which 
extracellular signals are transferred to the G proteins in the process of receptor transduction, although the mechanism that 
underlies this phenomenon still remains unsolved. Recently, it has been proposed that a trans-conformational switching 
model could be the mechanism allowing direct inhibition/activation of receptor activation/inhibition, respectively. Thus, 
heterotropic receptor-receptor allosteric regulations are behind the GPCR oligomeric function. In this paper we want to 
revise how GPCR oligomerization impinges on several important receptor functions like biosynthesis, plasma membrane 
diffusion or velocity, pharmacology and signaling. In particular, the rationale of receptor oligomerization might lie in the 
need of sensing complex whole cell extracellular signals and translating them into a simple computational model.  
Keywords: G protein-coupled receptor, protein-protein interaction, GPCR oligomerization. 
INTRODUCTION 
 The starting point of the GPCR oligomerization contest 
dates to the beginning of the eighties when two pieces of 
work proposed that GPCRs could interact at the level of the 
plasma membrane. First, it was postulated that an intermem-
brane interaction between the neuropeptide and the mono-
amine receptors was at the forefront of the functional cross-
talk observed between these two neurotransmitter systems, 
based on implicit functional evidence [1]. Also, in the same 
year it was shown that the β-adrenergic receptor agonist 
isoproterenol increased α2-adrenergic receptor binding in 
cortical slices [2]. Increased knowledge has been gained, by 
the use of radioligand-binding, of certain receptor-receptor 
interactions such as the interactions between cholecystokinin 
(CCK) and dopamine D2 receptors, CCKB and serotonin 5-
HT2 receptors, neurotensin and dopamine D2 receptors, vaso-
active intestinal peptide (VIP) and serotonin 5-HT1 recep-
tors, neuropeptide Y (NPY) and α2 adrenergic receptors, and 
neurokinin NK1 and 5-HT1 receptors (for review see [3]). 
After that, studies using photo-affinity labelling, radiation 
inactivation, cross-linking experiments and hydrodynamic 
analysis all supported the dimerization idea [4-7]. In the 
nineties, using electrophoretic mobility, coimmunopreci-
pitation and transcomplementation assays, first indications of 
GPCR homodimerization were encountered. By using the 
SDS-PAGE and Western blot approach it was possible to 
visualize GPCR homodimers as they were resistant to de-
naturing conditions (e.g. SDS and heat treatment) and 
receptor species of twice the expected molecular size were 
observed. For instance, 5-HT1B, D1 and D2 receptor homo-
dimers were shown to occur in cell lines [8-13]. The  
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existence of dopamine D2 and adenosine A1 receptor homo-
dimers in the brain was demonstrated also using this 
approach, showing their existence in native tissue and 
giving, for the first time, some impending relevance of the 
GPCR oligomerization phenomenon under physiological 
conditions [13, 14]. In the last decade the study of the qua-
ternary structure of GPCRs in living cells has been possible 
because of the development of biophysical techniques based 
on resonance energy transfer (RET), like bioluminescence-
RET (BRET) and fluorescence-RET (FRET), [3, 15-20]. 
Recently, the combination of RET-based methods together 
with bimolecular fluorescence/luminescence complemen-
tation techniques (BiFC and BiLC, respectively) as well as 
sequential BRET-FRET (SRET) being used as new 
fluorescence-based approaches have lent themselves to the 
identification of higher-order GPCR oligomers or receptor 
mosaics, helping to detect the existence of three or more 
receptors within the same oligomer [21-27]. Also, using 
some of the techniques mentioned above it was possible to 
isolate receptor homo- and heterodimers in order to study 
their distinctive pharmacodynamic properties, thus ascertain-
ing differences between receptor dimers and protomers with 
a potential relevance to drug discovery investigation. 
 Nowadays GPCR oligomerization is becoming widely 
accepted as a potential target in drug discovery despite some 
minor controversy [28]. The combination of all the informa-
tion provided by the experimental approaches described 
above unquestionably leads to the conclusion that GPCR 
oligomers exist in native tissue and that they might be 
relevant in normal and pathological conditions.  
MOLECULAR BASIS OF GPCR OLIGOMERIZA-
TION 
 Over the past few years, several studies of GPCR homo-
imerization have been focused on identifying key residua 
important in the phenomenon of GPCR oligomerization. It 
seems that the N-terminal domain disulphide bonds play an 
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important role in the homodimerization of some C family 
GPCRs like the metabotropic glutamate type 5 (mGlu5) 
receptor, the mGlu1α receptor and Ca
2+-sensing receptors. On 
the other hand, the C-terminal tail of another receptor of  
this family, namely the metabotropic γ-aminobutiric acid 
(GABA)B receptor, drives the heterodimerization of 
GABAB1R and GABAB2R by means of “coiled-coil” inter-
actions [29]. Alternatively, it seems that both intracellular 
and extra-cellular domains are eventually involved in the 
interface between some GPCR oligomers. In contrast, in 
studies conducted on a model of the rhodopsin dimer/ 
oligomer, the intradimeric contact was proposed to be loca-
ted within the transmembrane helix-IV and transmembrane 
helix-V (TM4 and TM5, respectively) [30]. Interestingly, 
these results are in contrast with the pioneering studies of 
Hebert and his colleagues [31], where the transmembrane 
helix-VI (TM6) of the β2-adrenergic receptor was said to 
participate in the homodimerization of the receptor, but they 
agree with the studies demonstrating that the interface of the 
dopamine D2 receptor homodimer is comprised within the 
TM4 [24, 32-34]. In addition, the participation of TM4 in the 
oligomer interface has been demonstrated for the serotonin 
5-HT2C receptor homodimer [35], the serotonin 5-HT4 
receptor homodimer [36], the chemokine CCR5 receptor 
homodimer [37], the α-factor pheromone receptor (Ste2) 
homodimer [38], the corticotrophin releasing hormone/VT2 
arginine vasotocin receptor heterodimer [39] and the 
serotonin 5-HT2A/mGlu2 receptor heterodimer [40]. 
 Nowadays, it is well accepted and to a certain extent 
demonstrated that the interaction interfaces of oligomeriza-
tion of the class A of GPCRs are formed by lipid-exposed 
surfaces within the transmembrane helical-bundle of each 
individual protomer (for review see [41]). Thus, it has been 
predicted that alterations in the receptor hydrophobic core 
may affect the receptor conformation and oligomerization. 
Interestingly, it has been recently proposed that GPCR 
oligomers need not be highly stable to function as oligomers 
[42]. This concept may make sense since transient oligo-
merization might allow, in theory, the exchange of protomers 
(i.e. during receptor activation). Of late, it has been proposed 
that the dynamics of oligomer association and dissociation 
may be subject to physiological regulation or pharmacolo-
gical intervention [42]. In general, two levels of interaction 
could be considered within the GPCR oligomer interface: the 
transmembrane helices and the intra- and extracellular 
domains (Fig. 1); and these, rather than being exclusive, 
work in a coordinated manner for the oligomer stabilization 
and function. 
 Indeed, a coulombic epitope-epitope interaction for the 
dopamine D2 receptor (D2R) and the adenosine A2A receptor 
(A2AR) has been described as a class A receptor intracellular 
interaction interface [43]. This interaction is based on an 
electrostatic attraction between a potentially phosphoryable 
serine/threonine domain (acidic motif) of the C-terminal tail 
of the A2AR and an arginine-rich, highly conserved epitope 
(basic motif), located within the third intracellular loop of 
the D2R. As a result, it can be hypothesized that phospho-
rylation/dephosphorylation events might regulate the 
oligomeric state of these receptors. In addition, it has been 
recently established that mutation of this serine reduces the 
ability of A2AR to interact with the D2R, [44] showing that 
the point mutation of the serine 374 in the A2AR/D2R 
eradicates the functional cross-talk observed between these 
two receptors when forming the heterodimer [44]. Overall, it 
can be suggested that by targeting the A2AR serine 374 it will 
be possible to allosterically modulate A2AR/D2R function. 
This might represent a new approach to the therapeutic 
modulation of D2R function. On the other hand, the subs-
titution of this serine by alanine doesn’t inhibit the ability of 
these receptors to co-immunoprecipitate, thus suggesting that 
the hydrophobic transmembrane receptor-receptor interac-
tion (see above) plays mostly a key structural role in stabi-
lizing the oligomer at the plasma membrane level, and on the 
other hand the coulombic interactions within the intracellular 
soluble domains would play mostly a regulatory (i.e. 
allosterical) role in controlling the heterodimer functionality 
(Fig. 1).  
 In the same way, it has recently been demonstrated that 
the third intracellular loop of the muscarinic acetylcholine 
M5 receptor (M5R) has a regulatory responsibility in receptor 
function and heteromerization [45]. Thus, a peptide derived 
from the M5R third intracellular loop reduced the degree of 
heterodimerization between the M5R and the M3R and 
abolished the carbachol-mediated ERK1/2 phosphorylation 
in cells coexpressing the M3R and the M5R [45]. The 
expression of the M5R third intracellular loop specifically 
targets the M3R/M5R heterodimeric function without 
affecting the individual M3R or M5R function.  
 Overall, it has been hypothesized that the interacting 
interfaces between two GPCRs in general, and the specific 
amino acids involved in the control of the heteromeric 
functionality in particular (i.e. the A2AR serine 374), might 
act as “check-points” along the allosteric communication 
pathways of a named receptor-receptor interaction [46].  
BIOSYNTHESIS AND PLASMA MEMBRANE DIFFU-
SION OF GPCR OLIGOMER  
 In order to reach the cell surface, the plasma membrane 
proteins (i.e. GPCRs), need to pass the ER/Golgi quality-
control system. Consequently, only the correctly folded 
receptors are able to pass through this control and be 
trafficked to the plasma membrane [47, 48]. For many 
proteins, oligomeric assembly has an important influence on 
the ER/Golgi quality control because it can mask specific 
retention signals or hydrophobic patches that would 
otherwise retain the proteins in the ER [49]. For GPCRs, the 
necessity of dimerization for correct transport to the plasma 
membrane (Fig. 1) has been shown with the GABABR, 
which is composed of two subunits, namely GABAB1R and 
GABAB2R [29, 50-52]. As such, GABAB1R and GABAB2R 
subunits interact initially in the ER and when only 
GABAB2R is present GABAB1R is targeted predominantly to 
the cell surface [50-52]. Now, it is well established that 
GABAB2R is as necessary for surface trafficking as G-
protein coupling with GABAB1R is necessary for agonist 
activation to conform functional GABABRs [29, 50-58]. 
 It has been shown by the combination of BiFC, which 
allows the detection of receptor oligomers at relatively low 
levels of expression, and fluorescence correlation spectro-
scopy (FCS) which is used to obtain quantative information 
such as plasma membrane diffusion or velocity of homo –
and oligomeric forms of some of the GPCRs, that once the 
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oligomers are at the cell surface they may be distributed in 
different plasma membrane domains, such as lipid rafts or 
caveolae and may also interact with other receptors. As 
described above, the rationale for  GPCR  oligomerization  is  
mainly concerned with the modulation of receptor func-
tionality. Related to this, the new unit made up of different 
receptors may be for example differently coupled to the 
signal transduction pathways, but it also may have acquired 
distinct characteristics, for instance concentration, associa-
tion or mobility, in the plasma membrane that would affect 
key cellular functions [59]. The heterodimer formed by A1R 
and A2AR was recently studied, as mentioned above, by 
combining the BiFC and FCS approaches [59]. The data 
obtained showed different plasma membrane diffusion 
coefficients when analyzing the results from individual co-
transfected cells. Interestingly, the heterodimer formed by 
A1R and A2AR diffused significantly faster than the respec-
tive homodimers, thus it had higher diffusion coefficients 
(D) and lower translational diffusion times (τD2) (D=5.6 
×10−9 cm2/s, τD2=12.9 ± 1.1 ms) than homodimers (D=5.0 
and 4.8 ×10−9 cm2/s and τD2=14.5 ± 1.5 ms and 15.0 ± 1.3 
ms for A1R and A2AR homodimers, respectively) (Fig. 1). 
Hence, it seems likely that oligomerization may change the 
receptor’s behavior, in terms of plasma membrane diffusion, 
a fact that could reflect either possible differences in their 
interaction with other proteins, such as cytoskeletal or 
 
Fig. (1). Role of oligomerization in the GPCR biology. Schematic representation highlighting some of the main themes connected to the 
concept of GPCR oligomerization. Both transmembrane and intra and extraceullular domains are involved in the GPCR oligomer interface. It 
has been suggested that these oligomer interfaces may act as allosteric “check-points”, modulating the information flow within a named 
GPCR oligomer [46], therefore playing a very important role in GPCR oligomer biology. Such roles, for example, include oligomer 
biosynthesis, membrane diffusion, pharmacology and signalling, as well as others. Ultimately, the stability of the oligomer will greatly 
depend on the behaviour of the oligomer interface dynamics, consequently, how these ‘check-points’ can be modulated by signals, for 
example allosteric modulators and phosphorylation events.  
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scaffolding proteins, or different interactions with the lipid 
environment of the plasma membrane [59, 60].  
THE CELL SIGNALLING CAN BE MODULATED BY 
GPCR OLIGOMERIZATION?  
 It has been demonstrated that GPCRs can mediate 
biological signals by stimulating nucleotide exchange in the 
heterotimeric G proteins (Gαβγ) after agonist challenge. 
Nowadays, investigators are trying to prove how the oligo-
merization of these receptors might impinge in the trans-
duction process by which these receptors transmit this signal 
to G proteins. In addition, these oligomers might act as 
coincidence detectors that control the extent and specificity 
of G-protein coupling. Thus, in some circumstances there is 
a synergistic increase of the receptor-mediated signalling 
when both agonists are present and in others the components 
of the heterodimers can negatively interact, thus attenuating 
signalling relative to the respective homodimers (Fig. 1). 
Interestingly, these situations have been studied in the α1AAR 
and α1BAR heterodimer [61], the M2R and M3R heterodimer 
[62] and the βAR and B2R [63]. 
 On the other hand, a loss of G-protein coupling following 
heterodimer formation for several GPCR oligomers has been 
observed, for instance the MOR and DOR heterodimer [64], 
the α2aAR and MOR heterodimer [65, 66], the CCR5 and 
CCR2 receptor heterodimer [67] and the A2AR and D2R 
heterodimer (For review see [68]). Related to this, it has 
been demonstrated that the oligomerization change the na-
ture of the interaction between the receptor and its associated 
G-protein (Fig. 1). For example, a change in the type of the 
G protein used for signalling has been observed for the 
D1R/D2R oligomer. Typically, the D1R couples to Gαs/olf and 
the D2R to the Gαi, but when these two receptors hetero-
dimerize, Gαq/11-mediated signalling occurs, thus producing 
an increase in phospholipase C activity and a rapid rise in 
intracellular calcium levels without affecting adenylate 
cyclase activity regulated by Gαs/olf and Gαi. Interestingly, 
this oligomer-specific G protein coupling requires the 
simultaneous activation of both D1R and D2R and it is 
regulated during brain development, thus being involved in 
synaptic plasticity [19]. Overall, a particular GPCR may 
exhibit variable G protein coupling as a result of hetero-
dimerization with diverse GPCR partners, thus generating an 
assortment of signalling phenotypes that greatly enrich the 
signal transduction process of a named receptor. 
GPCR OLIGOMERIZATION AND RECEPTOR 
PHARMACOLOGY 
 It has been shown that the phenomenon of oligomeriza-
tion of GPCRs permits more complex ligand-receptor 
interactions than those expected by the law of mass action 
and therefore expands the former concept of GPCRs being 
unique signalling units. The GPCR oligomer may alter 
receptor-agonist recognition by the formation of a new 
binding site with unique pharmacology (Fig. 1). For ins-
tance, it has been described that at the δ-opioid receptor 
(DOR) and κ-opioid receptor (KOR) heterodimer, 6’-
guanidinonaltrindole (6’-GNTI) acts as an agonist at the 
receptor but not at either homodimer [69], suggesting that 
this ligand represents a DOR/KOR oligomer-specific drug 
and demonstrating the pharmacological distinctiveness of the 
DOR/KOR oligomer. In addition to this, it has been shown 
that the 6’-GNTI has different effects depending on the 
administration site, thus spinal (but not central) administra-
tion leads to analgesia suggesting the need of a spatio-
temporal synchronization i.e. of the GPCR oligomerization 
phenomena in order to achieve effective receptor oligomers. 
Thus, to achieve an effective oligomerization the respective 
protomers need to be expressed at the same time and at the 
same place. Similarly, another GPCR oligomer-specific drug 
has been described, namely SKF83959 for the D1R/D2R 
heterodimer [19].  
 Jordan and Devi, in studies based on DOR and KOR 
ligand binding and functional experiments [70], studied the 
possible theory that GPCR oligomerization can play a key 
role in pharmacological diversity by promoting positive/ 
negative cooperativity within the protomers, forming a 
named oligomer. Although these two receptors oligomerize 
when coexpressed in the same cell, the heterodimer showed 
a very low affinity for either the δ− or the κ-selective ligand 
alone (i.e. [d-Pen2,d-Pen5]-enkephalin and U69593, respec-
tively). Interestingly, high affinity for these ligands was 
restored following the simultaneous combination of these 
two compounds, thus suggesting the existence of a positive 
cooperativity [70]. On the other hand, GPCR oligomer-
mediated ligand binding negative cooperativity has also been 
described (for review see [3]). 
 GPCR dimerization nowadays offers new opportunities 
for drug design and drug treatment. At least two strategies 
may be envisioned for GPCR heterodimers. Firstly, the co-
administration of two conventional drugs, targeting each of 
the two GPCR protomers contained within the heterodimer, 
and secondly, development of monovalent heterodimer- 
specific compounds [71]). An example of such a compound 
is MDAN-18, which is composed of both oxymorphone, a 
MOR agonist, and by naltrindole, a DOR antagonist [72]. 
Interestingly, these drugs displayed a higher anti-nociceptive 
activity when compared to that achieved by co-administra-
tion of the two individual ligands [72]. Finally, a set of 
compounds with great pharmacological potential interest are 
those that affect the stability of the GPCR oligomer (Fig. 1). 
Indeed, by specifically targeting the oligomer interface with 
small molecule drugs (i.e. allosteric modulators) (Fig. 1) it 
might be possible to preclude these receptor functions 
associated with the oligomer (for review see [41]. Overall, 
the quaternary structure of the GPCRs determines their func-
tionality, thus the control of the oligomer assembly/dis-
assembly will be a powerful pharmacological tool. 
FUTURE CHALLENGES 
 To conclude, the existence of GPCR oligomers has been 
largely demonstrated in heterologous expression systems 
where the respective protomers were often overexpressed, 
thus prompting the formation of artefacts (e.g. promotion or 
inhibition of protein-protein interactions). Related to this, it 
is believed that the GPCR oligomerization forms part of a 
cellular adaptive mechanism that increases the cell res-
ponsiveness in view of new environmental challenges. Thus, 
in order to fully understand the physiological relevance of 
this phenomenon, the real challenge consists in the in vivo 
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determination of GPCR oligomers in both normal and patho-
logical conditions. Interestingly, some hints about the signi-
ficance of GPCR olgomerization in health and disease has 
been initially revealed, for instance the oligomerization of 
β1- and β2ARs in the heart may play a critical role in the 
overall response of the heart to stimuli. Thus, it is suggested 
that in a healthy heart the high β1AR expression prevents 
growth-related signaling of β2ARs, whereas downregulation 
of βARs in response to excess of catecholamines may allow 
a previously blocked β2AR signaling pathways to proceed 
(for review see [73]). Also, the angiotensin II type 1 receptor 
(AT1R) and the bradykinin B2 receptor (B2R) oligomer has 
been shown to be increased in preeclamptic hypertensive 
women and proposed to be behind the angiotensin II-
mediated increased vasoconstriction and hypertension [74]. 
Thus, the magnitude of GPCR oligomerization in health and 
disease will be revealed in a near future. 
 For the in vivo occurrence of GPCR oligomers the spatio-
temporal synchronization of the receptor expression is very 
important (i.e. they should be transcribed and translated in 
the same place and at the same time). Interestingly, there is a 
hypothesis regarding the assembly of the heteromers in the 
ER/Golgi, making this area an important point in the 
heteromerization, where the oligomer interface should be 
properly folded and the “check-points” that regulate the flow 
of information between protomers are established. Only then 
can the GPCR oligomer travel to the plasma membrane 
where it will become fully functional (Fig. 1). Overall, from 
the pharmacological point of view the GPCR oligomeri-
zation phenomenon opens the door to more selective ther-
apies with reduced side effects. Therefore, the pharmaco-
logical complexity added by the receptor oligomerization 
phenomenon will, in the next couple of years propel the 
search for new drugs acting on specific GPCR oligomers, but 
before this these oligomers must be identified in order to be 
properly targeted. 
ABBREVIATIONS 
GPCR = G protein-coupled receptor 
CCK = Cholecystokinin 
VIP = Vasoactive intestinal peptide 
NPY = Neuropeptide Y 
NK = Neurokinin 
5-HT = 5-Hydroxytryptamine or serotonin 
GABA = γ-Aminobutiric acid 
mGlu = Metabotropic glutamate receptor 
D2R = Dopamine D2 receptor 
A2AR = Adenosine A2A receptor 
M5R = Muscarinic acetylcholine M5 receptor 
DOR = δ-Opioid receptor 
KOR = κ-Opioid receptor 
SDS- = Sodium dodecyl sulfate polyacrylamide gel  
PAGE   electrophoresis 
RET = Resonante energy transfer 
BRET = Bioluminescence-RET 
FRET = Fluorescente-RET 
BiFC = Bimolecular fluorescence complementation 
SRET = Sequential-RET 
TM = Transmembrane helix 
ER = Endoplasmic reticulum 
FCS = Fluorescence correlation spectroscopy 
6’-GNTI = 6’-Guanidinoaltrindole 
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